16 results on '"Takane, Hiroshi"'
Search Results
2. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy
- Author
-
Takane, Hiroshi, Miyata, Masanori, Burioka, Naoto, Shigemasa, Chiaki, Shimizu, Eiji, Otsubo, Kenji, and Ieiri, Ichiro
- Published
- 2006
- Full Text
- View/download PDF
3. Elevation of plasma D-dimer is closely associated with venous thrombosis produced by double-lumen catheter in pre-dialysis patients
- Author
-
Kanno, Yoshihiko, Kobayashi, Kazuhiro, Takane, Hiroshi, Arima, Hiroshi, Ikeda, Naofumi, Shoda, Junko, and Suzuki, Hiromichi
- Published
- 2007
4. Glucocorticoid Regulation of 24-Hour Oscillation in Interferon Receptor Gene Expression in Mouse Liver
- Author
-
Koyanagi, Satoru, Suyama, Hinako, Kuramoto, Yukako, Matsunaga, Noaya, Takane, Hiroshi, Soeda, Shinji, Shimeno, Hiroshi, Higuchi, Shun, and Ohdo, Shigehiro
- Published
- 2006
5. Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status
- Author
-
Hirota, Takeshi, Ieiri, Ichiro, Takane, Hiroshi, Maegawa, Shinji, Hosokawa, Masakiyo, Kobayashi, Kaoru, Chiba, Kan, Nanba, Eiji, Oshimura, Mitsuo, Sato, Tetsuo, Higuchi, Shun, and Otsubo, Kenji
- Published
- 2004
6. Height Constitutes an Important Predictor of Mortality in End-Stage Renal Disease.
- Author
-
Takenaka, Tsuneo, Sato, Takahiko, Hoshi, Hitoshi, Kato, Nobutaka, Sueyoshi, Keita, Tsuda, Masahiro, Watanabe, Yusuke, Takane, Hiroshi, Ohno, Yoichi, and Suzuki, Hiromichi
- Subjects
KIDNEY diseases ,HEMODIALYSIS ,TYPE 2 diabetes ,CARDIOVASCULAR diseases risk factors ,LOW density lipoproteins ,CARDIAC hypertrophy ,SMOKING - Abstract
Aim. Height is an important determinant of augmentation index (AI) that anticipates cardiovascular prognosis. There is a scanty of the data whether short height predicts survival in patients with end-stage renal diseases, a high risk population. Methods. Fifty two hypertensive patients with type 2 diabetic nephropathy receiving hemodialysis and 52 patients with nondiabetic nephropathy were enrolled. In addition to AI estimated with radial artery tonometry, classical cardiovascular risk factors were considered. Patients were followed for 2 years to assess cardiovascular prognosis. Results. Cox hazards regression revealed that both smoking and shortness in height independently contributed to total mortality and indicated that smoking as well as the presence of left ventricular hypertrophy predicted cardiovascular mortality. Our findings implicated that high AI, the presence of diabetes, and low high-density lipoprotein cholesterol were significant contributors to cardiovascular events. Conclusions. Our findings provide new evidence that shortness in height independently contributes to total mortality in hemodialysis patients. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases.
- Author
-
Takenaka, Tsuneo, Takane, Hiroshi, Okada, Hirokazu, Ohno, Yoichi, and Suzuki, Hiromichi
- Subjects
- *
CALCIUM antagonists , *RENIN-angiotensin system , *RENAL hypertension , *TREATMENT of chronic kidney failure , *KIDNEY diseases , *QUALITATIVE research , *PATIENTS - Abstract
The article focuses on the study relevant to the recommendation of the Japanese Society of Hypertension on calcium channel blockers (CCBs) as second line drugs next to the renin-angiotensin (Ang) system (RAS) inhibitor for hypertension with chronic kidney disease (CKD) treatment. It aims to find out the long-term effects of CCBs on arterial augmentation in CKD. It includes 26 non-diabetic CKD patients with amlodipine treatment and 27 patients on benidipine. The findings were discussed briefly.
- Published
- 2009
- Full Text
- View/download PDF
8. Association between DNA Methylation in the miR-328 5’-Flanking Region and Inter-individual Differences in miR-328 and BCRP Expression in Human Placenta.
- Author
-
Saito, Jumpei, Hirota, Takeshi, Furuta, Shinji, Kobayashi, Daisuke, Takane, Hiroshi, and Ieiri, Ichiro
- Subjects
DNA methylation ,MICRORNA ,NON-coding RNA ,INDIVIDUAL differences ,GENE expression ,PLACENTA physiology ,CANCER cell proteins ,DRUG resistance in cancer cells ,BREAST cancer treatment - Abstract
MicroRNA (miRNA) are non-coding small RNA that regulate gene expression. MiR-328 is reported to influence breast cancer resistance protein (BCRP) expression in cancer cells. As a large inter-individual difference in BCRP levels is observed in various human tissues, the contribution of miR-328 to these differences is of interest. We hypothesized that DNA methylation in the miR-328 promoter region is responsible for the difference in miR-328 levels, leading to inter-individual variability in BCRP levels in human placenta. The association between placental miR-328 and BCRP levels was analyzed, and then DNA methylation in the miR-328 5'-flanking region and regulatory mechanisms causing inter-individual differences in miR-328 and BCRP levels were examined. MiR-328 expression was significantly correlated with BCRP mRNA (Rs = -0.560, P < 0.01) and protein (Rs = -0.730, P < 0.01) levels. It was also up-regulated by the demethylating agent 5-aza-2’-deoxycytidine in BCRP-expressing cells. Luciferase assays with differentially methylated reporter constructs indicated that methylation in the miR-328 5’-flanking region including a predicted CpG island remarkably decreased transcriptional activity compared to that in unmethylated constructs. We selected CCAAT/enhancer binding protein α (C/EBPα), located within the predicted CpG island, by in silico analysis. To elucidate the role of C/EBPα in miR-328 expression, a chromatin immunoprecipitation assay, promoter deletion analysis, and electrophoretic mobility shift assay (EMSA) were performed. C/EBPα-binding site-truncated constructs showed significantly decreased promoter activity, and EMSA indicated that the C/EBPα-binding sites were located in the CpG island. Finally, the methylation patterns of several CpG dinucleotides proximal to two C/EBPα-binding sites in the miR-328 5’-flanking region were correlated negatively with miR-328 levels, and positively with BCRP levels in human placental samples. These results suggest that methylation patterns in the miR-328 5’-flanking region are involved in the inter-individual difference in BCRP levels in human placenta. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Successful Plasma Exchange for Acute Pancreatitis Complicated With Hypertriglyceridemia: A Case Report.
- Author
-
Takahira S, Suzuki H, Watanabe Y, Kin H, Ooya Y, Sekine Y, Sonoda K, Ogawa H, Nomura Y, Takane H, Tsuchiya Y, Tsukamoto I, and Nemoto M
- Abstract
A 33-year-old male with acute pancreatitis induced by hypertriglyceridemia had problems during treatment with plasma exchange. The hypercoagulable state was prevented by introducing innovative methods for cleaning and warming of the circuit and dialyzer. This enabled successful therapy, and the patient fully recovered from life-threatening acute pancreatitis.
- Published
- 2015
- Full Text
- View/download PDF
10. Statin improves flow-mediated vasodilation in chronic kidney diseases.
- Author
-
Takenaka T, Takane H, Kikuta T, Watanabe Y, and Suzuki H
- Abstract
Background. Numbers of drugs are required to manage patients with chronic kidney disease (CKD). Drug adherence is relatively poor in this population. Methods. In 36 CKD patients with hypertension and dyslipidemia, who were prescribing amlodipine 5 mg and atorvastatin 10 mg daily, the influences of exchanging to a combination drug containing equivalent doses of amlodipine and atorvastatin were observed for 6 months. Results. At the baseline, flow-mediated dilation (FMD) was reduced (2.4 ± 0.3%), and proteinuria was significantly contributed to decrements of FMD (R (2) = 0.38, F = 3.7, df (6,29), and P < 0.01). Six months later from exchanging to combination drug, total cholesterol (TC, 197 ± 5 to 183 ± 3 mg/dL, P < 0.01) and triglycerides (142 ± 14 to 129 ± 10 mg/dL, P < 0.05) were decreased, but high density lipoprotein cholesterol (53 ± 3 to 56 ± 3 mg/dL, P < 0.05) was increased. FMD was slightly albeit significantly improved to 2.7 ± 0.3% (P < 0.05). No serious adverse effects were seen by the combination drug. Subanalysis for the patients with considerable reductions of TC demonstrated that the combination drug decreased proteinuria and high sensitive CRP (P < 0.05 for both). Conclusion. Our data indicate that proteinuria constitutes a determinant of a reduced FMD. The present results implicate that combination drug is useful to improve adherence and suggest that atorvastatin refines endothelium function as well as lipid profiles in CKD patients.
- Published
- 2013
- Full Text
- View/download PDF
11. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.
- Author
-
Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, and Ieiri I
- Subjects
- Acetamides adverse effects, Acetamides therapeutic use, Adult, Aged, Aged, 80 and over, Anti-Infective Agents adverse effects, Anti-Infective Agents therapeutic use, Asian People, Female, Humans, Linezolid, Male, Middle Aged, Oxazolidinones adverse effects, Oxazolidinones therapeutic use, Acetamides pharmacokinetics, Anti-Infective Agents pharmacokinetics, Oxazolidinones pharmacokinetics, Thrombocytopenia chemically induced
- Abstract
Linezolid is an antimicrobial agent to treat infections by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). While effective, linezolid treatment frequently is associated with hematological side effects, especially thrombocytopenia. However, little is known about the mechanism of this side effect and the exposure-response relationship. The present population pharmacokinetic/pharmacodynamic (PPK/PD) study was undertaken to elucidate the factors that determine linezolid levels, the relationship between exposure to linezolid and a decrease in platelet counts, and appropriate dosage adjustments based on exposure levels. In total, 50 patients (135 plasma samples) were used for the PPK analysis. The PPK analysis revealed that renal function and severe liver cirrhosis (Child Pugh grade C) significantly affect the pharmacokinetics of linezolid according to the equation clearance (liter/h)=2.85×(creatinine clearance/60.9)0.618×0.472CIR (CIR indicates cirrhosis status; 0 for noncirrhosis, 1 for cirrhosis patients). Using 603 platelet counts from 45 patients, a PPK/PD analysis with a semimechanistic pharmacodynamic model described the relationship between linezolid exposure and platelet counts quantitatively, and the newly constructed model was validated using external data (776 platelet counts from 60 patients). Simulation indicated considerable risks in patients with insufficient renal function (creatinine clearance, ≤30 ml/min) or severe liver cirrhosis. For these patients, a reduced dosage (600 mg/day) would be recommended for sufficient efficacy (area under the concentration-time curve over 24 h in the steady state divided by the MIC, >100) and safety.
- Published
- 2011
- Full Text
- View/download PDF
12. Height constitutes an important predictor of mortality in end-stage renal disease.
- Author
-
Takenaka T, Sato T, Hoshi H, Kato N, Sueyoshi K, Tsuda M, Watanabe Y, Takane H, Ohno Y, and Suzuki H
- Abstract
Aim. Height is an important determinant of augmentation index (AI) that anticipates cardiovascular prognosis. There is a scanty of the data whether short height predicts survival in patients with end-stage renal diseases, a high risk population. Methods. Fifty two hypertensive patients with type 2 diabetic nephropathy receiving hemodialysis and 52 patients with nondiabetic nephropathy were enrolled. In addition to AI estimated with radial artery tonometry, classical cardiovascular risk factors were considered. Patients were followed for 2 years to assess cardiovascular prognosis. Results. Cox hazards regression revealed that both smoking and shortness in height independently contributed to total mortality and indicated that smoking as well as the presence of left ventricular hypertrophy predicted cardiovascular mortality. Our findings implicated that high AI, the presence of diabetes, and low high-density lipoprotein cholesterol were significant contributors to cardiovascular events. Conclusions. Our findings provide new evidence that shortness in height independently contributes to total mortality in hemodialysis patients.
- Published
- 2010
- Full Text
- View/download PDF
13. Cardio-ankle vascular index to screen cardiovascular diseases in patients with end-stage renal diseases.
- Author
-
Takenaka T, Hoshi H, Kato N, Kobayashi K, Takane H, Shoda J, and Suzuki H
- Subjects
- Aged, Blood Pressure, Diabetes Mellitus diagnosis, Female, Humans, Male, Mass Screening, Middle Aged, ROC Curve, Renal Dialysis, Sensitivity and Specificity, Ankle blood supply, Blood Vessels physiopathology, Cardiovascular Diseases complications, Cardiovascular Diseases diagnosis, Kidney Failure, Chronic complications, Kidney Failure, Chronic diagnosis
- Abstract
Background: Cardiovascular diseases constitute major causes of death in patients with chronic kidney diseases. An increase in arterial stiffness predicts the presence of cardiovascular diseases; however, non-invasive arterial stiffness parameters such as pulse wave velocity are confounded by blood pressure., Methods: A new arterial stiffness parameter beta for the arterial tree, cardio-ankle vascular index (CAVI), was measured. To examine the usefulness of CAVI to screen for the presence of cardiovascular diseases, cross-sectional studies were performed on 68 patients undergoing chronic hemodialysis., Results: Stepwise regression analysis indicated that CAVI significantly correlated to age (beta=0.05, p<0.01) but not blood pressure. In addition, CAVI was higher in diabetics than non-diabetics (8.39+/-0.37 vs 7.63+/-0.57, p<0.05). Furthermore, CAVI was markedly elevated in patients with a history of cardiovascular diseases (8.69+/-0.23 vs 6.66+/-0.28, p<0.01). Analysis using the ROC curve has demonstrated that CAVI of 7.55 constitutes the cut-off value for the presence of cardiovascular diseases with both sensitivity and specificity of 0.79., Conclusion: The present findings suggest that CAVI can be used as a screening test to detect for the presence of cardiovascular diseases in patients undergoing hemodialysis.
- Published
- 2008
- Full Text
- View/download PDF
14. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients.
- Author
-
Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H, and Suzuki H
- Subjects
- Aged, Calcium metabolism, Diabetes Mellitus, Type 2 drug therapy, Diabetic Nephropathies complications, Female, Humans, Hypertrophy, Left Ventricular complications, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Kidney Failure, Chronic therapy, Male, Middle Aged, Renal Dialysis, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents therapeutic use, Diabetes Mellitus, Type 2 complications, Diabetic Nephropathies therapy, Hypertrophy, Left Ventricular drug therapy, Kidney Failure, Chronic complications, Losartan therapeutic use
- Abstract
Background: Left ventricular hypertrophy (LVH) is frequently found at the initiation of dialysis therapy for diabetic and hypertensive patients, and is highly predictive of future cardiac morbidity and mortality. Angiotensin type 1 receptor (AT1) antagonists may be able to regress LVH by mechanisms independent of their antihypertensive effects in diabetic patients. It is not known whether AT1 antagonists are able to reverse LVH in diabetic patients on dialysis therapy., Method: Twenty-four type II diabetic patients with end-stage renal disease who had just entered into hemodialysis therapy, and were diagnosed as having LVH evaluated by echocardiography, were selected from 3 dialysis units staffed by the faculty of Saitama Medical School between 1998 and 2001. The study was carried out for 1 year. All patients were randomly assigned to 2 groups. One group received an AT 1 antagonist, losartan 100 mg daily 30 minutes after the cessation of dialysis therapy on dialysis days, or in the evening when dialysis therapy did not occur. The control group received placebo. LVH was evaluated by echocardiography before the start of administration of drugs, at 4 and 8 months, and again at 12 months after the start of drug therapy. A systolic blood pressure of less than 140 mm Hg was the target blood pressure in both groups., Results: Using repeated measures analysis of variance, applied to those with 4 echocardiograms, there were progressive decreases over time in the left ventricular mass index (LVMi), posterior wall thickness, and intraventricular wall thickness in patients receiving losartan. The biggest changes in mass and the other parameters occurred between baseline and at month 6. Compared with these changes in the patients receiving losartan, left ventricular internal diameters and their derived parameters (e.g., ejection fraction) remained unchanged throughout the study. In spite of a similar reduction of bp in the patients receiving placebo, no significant changes in echocardiographic parameters were found in these patients., Conclusion: An AT 1 antagonist, losartan, is beneficial for the regression of LVH in diabetic patients who started dialysis therapy under adequate blood pressure control.
- Published
- 2004
- Full Text
- View/download PDF
15. Relationship between 24-hour rhythm in antiviral effect of interferon-beta and interferon-alpha/beta receptor expression in mice.
- Author
-
Takane H, Ohdo S, Baba R, Koyanagi S, Yukawa E, and Higuchi S
- Subjects
- 2',5'-Oligoadenylate Synthetase metabolism, Animals, Antiviral Agents administration & dosage, Antiviral Agents blood, Body Temperature drug effects, Cyclooxygenase 1, Cyclooxygenase 2, Hypothalamus metabolism, Injections, Intravenous, Interferon-beta administration & dosage, Interferon-beta blood, Isoenzymes metabolism, Liver drug effects, Liver metabolism, Lymphocytes drug effects, Lymphocytes metabolism, Male, Membrane Proteins, Mice, Mice, Inbred ICR, Prostaglandin-Endoperoxide Synthases metabolism, RNA, Messenger metabolism, Receptor, Interferon alpha-beta, Receptors, Interferon metabolism, Reverse Transcriptase Polymerase Chain Reaction, Antiviral Agents pharmacology, Circadian Rhythm, Interferon-beta pharmacology, Receptors, Interferon drug effects
- Abstract
The influence of interferon-beta (IFN-beta) dosing time on antiviral activity was investigated in ICR male mice under light-dark cycle conditions (lights on at 07:00, off at 19:00) with food and water available ad libitum. There was a significant dosing time-dependent change in 2',5'-oligoadenylate synthetase (2',5'-OAS) activities, as an index of antiviral activity, in liver at 12 h after IFN-beta (15 MIU/kg, i.v.) injection. IFN-beta-induced 2',5'-OAS activity was more potent after the drug injection during the late dark phase. The higher antiviral effect of IFN-beta was observed when the interferon-alpha/beta receptor (IFNAR) expression in the liver increased, and the lower effect was observed when its expression decreased. IFN-beta-induced fever was more serious after IFN-beta injection from the late dark phase to the early light phase. A significant dosing time-dependent change was demonstrated for plasma IFN-beta concentrations, which showed a higher level during the light phase and a lower level during the dark phase. The dosing time-dependent change of plasma IFN-beta concentrations was not associated with that of the antiviral effect or fever induced by IFN-beta. These results suggest that selecting the most suitable dosing time of IFN-beta, associated with the 24-h rhythm of IFNAR expression in the liver, may be important to increase effectively the antiviral activity of the drug in experimental and clinical situations.
- Published
- 2002
- Full Text
- View/download PDF
16. Daily expression of mRNAs for the mammalian Clock genes Per2 and clock in mouse suprachiasmatic nuclei and liver and human peripheral blood mononuclear cells.
- Author
-
Takata M, Burioka N, Ohdo S, Takane H, Terazono H, Miyata M, Sako T, Suyama H, Fukuoka Y, Tomita K, and Shimizu E
- Subjects
- Adult, Animals, CLOCK Proteins, Cell Cycle Proteins, Female, Gene Expression, Humans, Leukocytes, Mononuclear metabolism, Male, Mice, Mice, Inbred ICR, Nuclear Proteins genetics, Period Circadian Proteins, Reverse Transcriptase Polymerase Chain Reaction, Species Specificity, Time Factors, Trans-Activators genetics, Transcription Factors, Circadian Rhythm, Liver metabolism, Nuclear Proteins metabolism, RNA, Messenger metabolism, Suprachiasmatic Nucleus metabolism, Trans-Activators metabolism
- Abstract
The mammalian circadian clock is located in the suprachiasmatic nucleus (SCN) of the hypothalamus and in most peripheral tissues. Clock genes drive the biological clock. However, circadian expression variations of the human clock genes are still unclear. In this study, we analyzed the daily variations of mPer2 and mClock mRNA expression in both the mouse SCN and liver to evaluate the central and peripheral alterations in the rodent clock genes. We also examined whether there are the daily variations of the clock genes hPer2 and hClock in human peripheral blood mononuclear cells (PBMCs). The daily variation of mClock and mPer2 mRNA expression in mouse SCN and liver were determined at ZT2, ZT6, ZT10, ZT14, ZT18 or ZT22. We isolated PBMCs from 9 healthy volunteers at 9:00 and 21:00 and examined the expression of hPer2 and hClock mRNA by RT-PCR analysis. The animals exhibited a robust daily rhythm in the RNA levels of mPer2 in the SCN and liver (P<0.01, respectively). In humans, hPer2 mRNA expression also had daily variation, and the hPer2 mRNA levels at 9:00 were significantly larger than those at 21:00 (P<0.01). While, the Clock mRNA in both mice and humans exhibited no daily variation. These findings suggest that the variation in hPer2 mRNA expression may be useful for assessing human peripheral circadian systems.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.